Researchers Identify Protein That Weakens CAR T-Cell Therapy, Find a Way to Boost Its Effectiveness
Similar Articles
Modified CAR-T Cell Therapy Shows Promising HIV Suppression in Early Trial
Scientists Develop Drug Method to Boost Natural Killer Cells Against Multiple Cancers
New Imaging Technique Reveals Immune Cell Killing Machinery
New Drugs Target 'Zombie' Cells to Combat Cancer and Aging
Amino Acid Supplement Boosts mRNA Delivery and Gene Editing Efficiency
Scientists have discovered a protein that causes CAR T-cell therapy to lose its potency over time. By using gene editing to remove this protein in lab models, they created more durable and effective cancer-fighting cells. This finding could lead to improved treatments for patients.
Facts First
- A protein called NFIL3 contributes to CAR T cells weakening over time, limiting their cancer-fighting ability.
- Using CRISPR/Cas9 to disable the NFIL3 gene made the engineered cells more effective in mouse models.
- Edited CAR T cells stayed active longer, multiplied more, and controlled tumors better, extending survival.
- The research was led by teams from Columbia University and University Hospital Tübingen and published in Cancer Discovery.
- The work is part of Germany's only oncology Cluster of Excellence, iFIT (Image Guided and Functionally Instructed Tumor Therapies).
What Happened
An international research team identified a protein, NFIL3, that causes CAR T cells to weaken during cancer treatment. The team conducted a large-scale analysis of about 400 transcription factors to find factors limiting the therapy's performance. Using CRISPR/Cas9 gene-editing technology, they disabled the gene responsible for producing NFIL3. In mouse models, the modified CAR T cells lacking NFIL3 were more effective at controlling tumors and helped extend survival.
Why this Matters to You
If you or a loved one faces a cancer treatable with CAR T-cell therapy, this research could lead to more effective and longer-lasting treatments in the future. The discovery suggests that future therapies might be engineered to overcome a key limitation, which could improve patient outcomes. While still in the research phase, this finding opens a new path for enhancing a powerful form of immunotherapy.
What's Next
The findings, published in the journal Cancer Discovery, provide a specific target for improving CAR T-cell therapies. Further research will be needed to translate this discovery from mouse models into safe and effective treatments for human patients. The work conducted within the iFIT Cluster of Excellence indicates a focused effort to advance this type of guided cancer therapy.